[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100494533":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":30,"responsibleParty":49,"collaborators":11,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":11,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":11,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":11,"overallStatus":33,"whyStopped":11,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Jewish General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Pre and post BPA","EXPERIMENTAL",null,[13],"Other: Measurement of pulmonary functional capillary surface area",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":11},"Measurement of pulmonary functional capillary surface area","Measurement of transpulmonary metabolism of trace injected doses of benzoyl-Phe-Ala-Pro",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"David Langleben, MD","CONTACT","5143407531","david.langleben@mcgill.ca",{"name":26,"role":22,"phone":27,"phoneExt":28,"email":29},"Lyda Lesenko, MD","514-340-8222","22833","llesenko@jgh.mcgill.ca",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"David Langleben","RECRUITING","Montreal","Quebec","H3W 2C4","Canada","CA",{"type":40,"coordinates":41},"Point",[42,43],-73.58781,45.50884,{"lat":43,"lon":42},[46,47],{"name":32,"role":22,"phone":23,"phoneExt":11,"email":24},{"name":21,"role":48,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"type":48,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Dr David Langleben","Professor of Medicine","100494533","functional-pulmonary-capillary-surface-area-in-bpa-for-cteph-100494533",false,"NCT05719415","Functional Pulmonary Capillary Surface Area in BPA for CTEPH","Assessment of Recovery of Functional Capillary Surface Area in Patients Undergoing a Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension","Inclusion Criteria:\n\n* All patients eligible for balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension\n\nExclusion Criteria:\n\n* Treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers,\n* Presence of patent foramen ovale","ALL","18 Years","75 Years",{"count":63,"type":64},40,"ESTIMATED","INTERVENTIONAL",[67],"NA","Chronic thromboembolic pulmonary hypertension \\[CTEPH\\] is caused by pulmonary emboli that have enlarged in pulmonary arteries and have become organized into the vessel wall. Many patients with CTEPH are treated with balloon pulmonary angioplasty \\[BPA\\] which mechanically opens the narrow pulmonary arteries. It is unclear how much downstream functional pulmonary capillary surface area \\[FCSA\\] is recovered during BPA. The investigators plan to measure FCSAIn CTEPH patients, before and after a session of BPA.",[70,71],"Hypertension, Pulmonary","Pulmonary Thromboembolisms","2025-09-22",{"date":74,"type":75},"2025-09-23","ACTUAL",{"date":77,"type":75},"2023-03-23",{"date":79,"type":64},"2028-01-30",{"name":5,"class":6},1]